Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print September 7, 2005, doi:10.1212/01.wnl.0000176987.47875.28)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000176987.47875.28v1
65/9/1460    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aharon-Peretz, J.
Right arrow Articles by Gershoni-Baruch, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aharon-Peretz, J.
Right arrow Articles by Gershoni-Baruch, R.
Received January 21, 2005
Accepted June 20, 2005

Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype-genotype correlation

Judith Aharon-Peretz MD*, Samih Badarny MD, Hanna Rosenbaum MD, and Ruth Gershoni-Baruch MD

From the Department of Neurology and the Cognitive Neurology Unit, Hematology and Bone Marrow Transplantation and Human Genetics, Rambam Medical Center; Department of Neurology, Carmel Medical Center; and the Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.


* To whom correspondence should be addressed. E-mail: jaharon{at}rambam.health.gov.il.

Abstract-- Mutations in the glucocerebrosidase (GBA) gene have been recently identified as contributory to Parkinson disease (PD) in Ashkenazi Jews. In the present study, the clinical characteristics of Ashkenazi patients with PD with GBA mutations (n = 40) were compared to those of Ashkenazi patients with PD without any known GBA mutation (n = 108). The overall clinical manifestations and age at disease onset did not differ in patients with GBA mutations compared to patients without mutations.




This article has been cited by other articles:


Home page
 haematolHome page
M. Di Rocco, F. Giona, F. Carubbi, S. Linari, F. Minichilli, R. O. Brady, G. Mariani, and M. D. Cappellini
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease
Haematologica, August 1, 2008; 93(8): 1211 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
Y.-R. Wu, C.-M. Chen, C.-Y. Chao, L.-S. Ro, R.-K. Lyu, K.-H. Chang, and G.-J. Lee-Chen
Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese
J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 977 - 979.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E.-K. Tan, J. Tong, S. Fook-Chong, Y. Yih, M.-C. Wong, R. Pavanni, and Y. Zhao
Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients
Arch Neurol, July 1, 2007; 64(7): 1056 - 1058.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.